U.S., March 26 -- ClinicalTrials.gov registry received information related to the study (NCT06894212) titled 'A Trial of the Efficacy and Safety of SEP-363856 in Acutely Psychotic Participants With Schizophrenia' on Feb. 27.
Brief Summary: This is a Phase 3, Multicenter, Randomized, Double-blind, Placebo-controlled Trial to Determine the the Efficacy and Safety of SEP-363856 in Acutely Psychotic Participants with Schizophrenia
Study Start Date: Feb. 25
Study Type: INTERVENTIONAL
Condition:
Schizophrenia
Intervention:
DRUG: SEP-363856
tablet
OTHER: Placebo
tablet
Recruitment Status: RECRUITING
Sponsor: Otsuka Pharmaceutical Development & Commercialization, Inc.
Disclaimer: Curated by HT Syndication....